Rabbit Anti-ARID1A Recombinant Antibody (D2A8U) (CBMAB-A3541-YC)

Name: Rabbit Anti-ARID1A Recombinant Antibody (D2A8U)
SKU: CBMAB-A3541-YC
Rating: 5 (1 reviews)

See all ARID1A antibodies

Compare Online Inquiry

Published Data

Rabbit Anti-ARID1A Recombinant Antibody (D2A8U) CBMAB-A3541-YC in ICC

Immunocytochemistry and statistical analysis of MSH2 foci formation in control and ARID1A-knockdown HeLa cells. Dashed square, magnification of area. Early S phase, 1 h after thymidine release; G2/M phase, 8 h after thymidine release. Scale bars, 10 μ m. Data represent mean ± s.e.m. (Early S phage: shCtrl, 60.38 ± 2.976%, n = 250 cells; shARID1A_1, 12.05 ± 1.346%, n = 168 cells; shARID1A_2, 15.11 ± 1.891%, n = 121 cells; G2/M phage: shCtrl, 7.974 ± 1.597%, n = 345 cells; shARID1A_1, 6.008 ± 1.661%, n = 472 cells; shARID1A_2, 7.218 ± 0.47%, n = 179 cells; from 3 independent experiments; one-way ANOVA). i, MSH2 foci at early S phase in ARID1A-null OAW42 cells. Scale bars, 10 μ m. ...View More

Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., ... & Peng, G. (2018). ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nature medicine, 24(5), 556-562.

Rabbit Anti-ARID1A Recombinant Antibody (D2A8U) CBMAB-A3541-YC in IHC

Immunohistochemistry for ARID1A (brown) in the breast cancer tissue. ...View More

Wang, Y., Chen, X., Qiao, X., Xie, Y., Guo, D., Li, B., ... & Hu, X. (2023). Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP. Cancers, 15(9), 2447.

Rabbit Anti-ARID1A Recombinant Antibody (D2A8U) CBMAB-A3541-YC in WB

Western blot of ARID1A expression in siRNA-treated 12Z cells. β-Actin was used as endogenous control. ...View More

Wilson, M. R., Reske, J. J., Holladay, J., Wilber, G. E., Rhodes, M., Koeman, J., ... & Chandler, R. L. (2019). ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nature communications, 10(1), 3554.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Rabbit

Clone

D2A8U

Application

WB, IHC-P, IP

Immunogen

Synthetic peptide corresponding to residues surrounding Gly1293 of human ARID1A/BAF250A protein.

Specificity

Human, Mouse, Rat, Monkey

Antibody Isotype

IgG

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:1,000
IHC-P	1:500-1:2,000
IP	1:100

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

10mM HEPES, pH 7.5, 0.15M NaCl, 0.1mg/mL BSA, 50% Glycerol

Preservative

0.02% sodium azide

Concentration

Batch dependent

Storage

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

AT-Rich Interaction Domain 1A

Introduction

ARID1A is a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dep

Entrez Gene ID

Human	8289
Mouse	93760
Rat	297867
Monkey	719949

UniProt ID

Human	O14497
Mouse	A2BH40
Rat	D4A3E3
Monkey	F7DX53

Alternative Names

AT-Rich Interaction Domain 1A; SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator Of Chromatin Subfamily F Member 1; AT Rich Interactive Domain 1A (SWI-Like); ARID Domain-Containing Protein 1A; SWI/SNF Complex Protein P270; BRG1-Associated Fact

Function

Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. Binds DNA non-specifically. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity).

Biological Process

Androgen receptor signaling pathway Source: UniProtKB
ATP-dependent chromatin remodeling Source: GO_Central
Chromatin-mediated maintenance of transcription Source: UniProtKB
Chromatin remodeling Source: BHF-UCL
Glucocorticoid receptor signaling pathway Source: UniProtKB
Intracellular estrogen receptor signaling pathway Source: UniProtKB
Nervous system development Source: UniProtKB-KW
Nucleosome disassembly Source: BHF-UCL
Nucleosome mobilization Source: UniProtKB
Positive regulation of transcription, DNA-templated Source: UniProtKB
Regulation of transcription by RNA polymerase II Source: GO_Central

Cellular Location

Nucleus

Involvement in disease

Coffin-Siris syndrome 2 (CSS2): A form of Coffin-Siris syndrome, a congenital multiple malformation syndrome with broad phenotypic and genetic variability. Cardinal features are intellectual disability, coarse facial features, hypertrichosis, and hypoplastic or absent fifth digit nails or phalanges. Additional features include malformations of the cardiac, gastrointestinal, genitourinary, and/or central nervous systems. Sucking/feeding difficulties, poor growth, ophthalmologic abnormalities, hearing impairment, and spinal anomalies are common findings. Both autosomal dominant and autosomal recessive inheritance patterns have been reported.

Lee, C. G., & Ki, C. S. (2021). A Novel De Novo Heterozygous ARID1A Missense Variant Cluster in cis c.[5954C> G; 6314C> T; 6334C> T; 6843G> C] causes a Coffin–Siris Syndrome. Annals of Laboratory Medicine, 41(3), 350.

Qadir, J., Majid, S., Khan, M. S., Rashid, F., Wani, M. D., Din, I., & Bashir, H. (2020). AT-rich interaction domain 1A gene variations: genetic associations and susceptibility to gastric cancer risk. Pathology & Oncology Research, 26(4), 2237-2246.

Okamura, R., Kato, S., Lee, S., Jimenez, R. E., Sicklick, J. K., & Kurzrock, R. (2020). ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer, 8(1).

Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., ... & Gupta, S. (2020). Paradoxical role of AT-rich interactive domain 1A in restraining pancreatic carcinogenesis. Cancers, 12(9), 2695.

Hu, G., Tu, W., Yang, L., Peng, G., & Yang, L. (2020). ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. Cancer letters, 473, 148-155.

Raffone, A., Travaglino, A., Saccone, G., Cieri, M., Mascolo, M., Mollo, A., ... & Zullo, F. (2019). Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. Apmis, 127(9), 597-606.

Zhou, H., Tan, S., Li, H., & Lin, X. (2019). Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma. Molecular medicine reports, 19(3), 2125-2136.

Bui, C. B., Le, H. K., Vu, D. M., Truong, K. D. D., Nguyen, N. M., Ho, M. A. N., & Truong, D. Q. (2019). ARID1A‐SIN3A drives retinoic acid‐induced neuroblastoma differentiation by transcriptional repression of TERT. Molecular carcinogenesis, 58(11), 1998-2007.

Zhang, L., Wang, C., Yu, S., Jia, C., Yan, J., Lu, Z., & Chen, J. (2018). Loss of ARID1A expression correlates with tumor differentiation and tumor progression stage in pancreatic ductal adenocarcinoma. Technology in cancer research & treatment, 17, 1533034618754475.

Hu, C., Li, W., Tian, F., Jiang, K., Liu, X., Cen, J., ... & Hui, L. (2018). Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. Journal of hepatology, 68(3), 465-475.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Rabbit Anti-ARID1A Recombinant Antibody (D2A8U)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Mouse Anti-ARID1A Recombinant Antibody (3611) (CAT#: CBMAB-A3539-YC)

Mouse Anti-ARID1A Recombinant Antibody (CBYC-A764) (CAT#: CBMAB-A3543-YC)

Mouse Anti-ARID1A Recombinant Antibody (C-7) (CAT#: CBMAB-A3540-YC)

Mouse Anti-ARID1A Recombinant Antibody (PSG3) (CAT#: CBMAB-A3542-YC)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry